Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone

被引:3
|
作者
da Silva, Eveline Santos [1 ]
Servais, Jean-Yves [1 ]
Kohnen, Michel [2 ]
Arendt, Victor [2 ]
Gilson, Georges [2 ]
Staub, Therese [2 ]
Seguin-Devaux, Carole [1 ]
Perez-Bercoff, Danielle [1 ]
机构
[1] Luxembourg Inst Hlth, Dept Infect & Immun, HIV Clin & Translat Res Unit, 29 Rue Henri Koch, L-4354 Esch Sur Alzette, Luxembourg
[2] Ctr Hosp Luxembourg, 4 Rue Ernest Barble, L-1210 Luxembourg, Luxembourg
关键词
SARS-CoV-2; neutralization; vaccination; hybrid immunity; breakthrough infection; Omicron BA; 1; BA; 2; 4; 5; IMMUNODEFICIENCY-VIRUS TYPE-1; SARS-COV-2; OMICRON; CONVALESCENT; MATURATION; ANTIBODIES; RESISTANCE; BREADTH; POTENCY;
D O I
10.3390/cimb45020112
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Since the emergence of SARS-CoV-2 Omicron BA.1 and BA.2, several Omicron sublineages have emerged, supplanting their predecessors. Here we compared the neutralization of Omicron sublineages BA.1, BA.2, BA.4 and BA.5 by human sera collected from individuals who were infected with the ancestral B.1 (D614G) strain, who were vaccinated (3 doses) or with breakthrough infection with pre-Omicron strains (Gamma or Delta). All Omicron sublineages exhibited extensive escape from all sera when compared to the ancestral B.1 strain and to Delta, albeit to different levels depending on the origin of the sera. Convalescent sera were unable to neutralize BA.1, and partly neutralized BA.2, BA.4 and BA.5. Vaccinee sera partly neutralized BA.2, but BA.1, BA.4 and BA.5 evaded neutralizing antibodies (NAb). Some breakthrough infections (BTI) sera were non-neutralizing. Neutralizing BTI sera had similar neutralizing ability against all Omicron sublineages. Despite similar levels of anti-Spike and anti-Receptor Binding Domain (RBD) antibodies in all groups, BTI sera had the highest cross-neutralizing ability against all Omicron sublineages and convalescent sera were the least neutralizing. Antibody avidity inferred from the NT50:antibody titer ratio was highest in sera from BTI patients, underscoring qualitative differences in antibodies elicited by infection or vaccination. Together, these findings highlight the importance of vaccination to trigger highly cross-reactive antibodies that neutralize phylogenetically and antigenically distant strains, and suggest that immune imprinting by first generation vaccines may restrict, but not abolish, cross-neutralization.
引用
收藏
页码:1741 / 1761
页数:21
相关论文
共 50 条
  • [21] Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies
    Zhou, Hao
    Dcosta, Belinda M.
    Landau, Nathaniel R.
    Tada, Takuya
    VIRUSES-BASEL, 2022, 14 (06):
  • [22] Outcomes of Omicron sub-lineages BA.1.1 and BA.2 infection compared with the sub-lineage BA.1 infection in emergency departments' patients
    Bouzid, Donia
    Kapfer, Thomas
    Marot, Stephane
    Ing, Vittiaroat
    Ferre, Valentine Marie
    Chauvin, Anthony
    Le Goff, Jerome
    Ellouze, Sami
    Salmona, Maud
    Hermand, Christelle
    Bourg, Arthur
    Schnuriger, Aurelie
    Femy, Florent
    Tinh, Meryl Nguyen Van
    Brichler, Segolene
    Veyer, David
    Le Borgne, Pierrick
    Fafi-Kremer, Samira
    L'Honneur, Anne Sophie
    Augustin, Clement
    Simon, Tabassome
    Cachanado, Marine
    Freund, Yonathan
    CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (04) : 551 - 553
  • [23] Molecular mechanisms responsible for SARS-CoV-2 antibody waning and vaccine escape in Omicron sublineages BA.4 and BA.5
    Hewins, Benjamin
    Richardson, Christopher
    Rubino, Salvatore
    Kelvin, Alyson
    Ostadgavahi, Ali Toloue
    Kelvin, David J.
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2022, 16 (07): : 1122 - 1125
  • [24] Effectiveness of the severe acute respiratory syndrome coronavirus 2 Omicron BA.5 bivalent vaccine on symptoms in healthcare workers with BA.5 infection
    Hirotsu, Yosuke
    Takatori, Mika
    Mochizuki, Hitoshi
    Omata, Masao
    VACCINE: X, 2024, 17
  • [25] Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission
    Shrestha, Lok Bahadur
    Foster, Charles
    Rawlinson, William
    Tedla, Nicodemus
    Bull, Rowena A.
    REVIEWS IN MEDICAL VIROLOGY, 2022, 32 (05)
  • [26] Fifth bivalent omicron BA.4/BA.5 vaccination neutralization of SARS-CoV-2 in heart transplant recipients
    Peled, Yael
    Afek, Arnon
    Patel, Jignesh K.
    Raanani, Ehud
    Segev, Amit
    Ram, Eilon
    Fardman, Alexander
    Beigel, Roy
    Atari, Nofar
    Kliker, Limor
    Abd Elkader, Bayan
    Mandelboim, Michal
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2023, 42 (08) : 1054 - 1058
  • [27] Case Report: Omicron BA.2 Subvariant of SARS-CoV-2 Outcompetes BA.1 in Two Co-infection Cases
    Gjorgjievska, Marija
    Mehandziska, Sanja
    Stajkovska, Aleksandra
    Pecioska-Dokuzovska, Slavica
    Dimovska, Anica
    Durmish, Idriz
    Ismail, Sara
    Pavlovska, Teodora
    Stojchevska, Antonija
    Amedi, Haris
    Andonova, Jasna
    Nikolovska, Marija
    Velickovikj, Sara
    Mitrev, Zan
    Kungulovski, Ivan
    Kungulovski, Goran
    FRONTIERS IN GENETICS, 2022, 13
  • [28] Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-na?ve and previously-infected individuals
    Kuzel, Timothy G.
    Fu, Jia
    Anderson, Mark
    Stec, Michael
    Boler, Michael
    Behun, Dylan
    Gosha, Amy
    Cloherty, Gavin
    Landay, Alan
    Moy, James
    VACCINE, 2023, 41 (04) : 879 - 882
  • [29] Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies
    Wilhelm, Alexander
    Widera, Marek
    Grikscheit, Katharina
    Toptan, Tuna
    Schenk, Barbara
    Pallas, Christiane
    Metzler, Melinda
    Kohmer, Niko
    Hoehl, Sebastian
    Marschalek, Rolf
    Herrmann, Eva
    Helfritz, Fabian A.
    Wolf, Timo
    Goetsch, Udo
    Ciesek, Sandra
    EBIOMEDICINE, 2022, 82
  • [30] Differences in Presentation of SARS-CoV-2 Omicron Strain Variant BA.1–BA.5 Peptides by HLA Molecules
    S. A. Nersisyan
    M. Yu. Shkurnikov
    A. P. Zhiyanov
    V. O. Novosad
    A. G. Tonevitsky
    Doklady Biochemistry and Biophysics, 2022, 507 : 298 - 301